CEO Jonathan Javitt (NeuroRx)

Neu­roRx chief lines up Hail Mary for once-re­ject­ed Covid-19 drug

Neu­roRx’s Covid-19 treat­ment was al­ready shot down by the FDA once, and it failed the pri­ma­ry end­point in a Phase IIb/III read­out — but that won’t stop CEO Jonathan Javitt from lin­ing up a Hail Mary pass to reg­u­la­tors.

Javitt gave End­points News a pre­view of Phase IIb/III da­ta based on an ini­tial 28-day end­point on Mon­day af­ter­noon. At 28 days, crit­i­cal­ly ill Covid-19 pa­tients giv­en Neu­roRx and Re­lief Ther­a­peu­tics’ avip­tadil were 35% more like­ly to re­cov­er and be dis­charged from the hos­pi­tal com­pared to those on a place­bo, Javitt said. How­ev­er, the p-val­ue was 0.08 — falling well be­low the 0.05 p-val­ue need­ed to demon­strate sta­tis­ti­cal sig­nif­i­cance, mean­ing there’s a greater chance that the re­sults were ran­dom and not tied to the treat­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.